Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration

Frontiers in Pharmacology

Volumn 3 MAR, Issue , 2012, Pages

  Peyton, Kelly J ^a   Shebib, Ahmad R ^a   Azam, Mohammad A ^a   Liu, Xiao Ming ^a   Tulis, David A ^b   Durante, William ^a  

^a University of Missouri   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Bilirubin; Migration; Proliferation; Stenosis; Vascular smooth muscle cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; BILIRUBIN; CYCLIN A; CYCLIN D1; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CAROTID ARTERY INJURY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; NEOINTIMA; NONHUMAN; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER;

EID: 84865964718     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00048     Document Type: Article

References (57)

1. Aizawa, T., Ishizaka, N., Taguchi, J., Kimura,S.,Kurokawa,K.,and Ohno, M. (1999). Balloon injury does not induce heme oxygenase-1 gene expression, but administration of hemin inhibits neointimal formation in balloon injured rat carotid arteries. Biochem. Biophys. Res. Commun. 261, 302-307.
2. Clark, J. E., Foresti, R., Green, C. J., and Motterlini, R. (2000). Dynamics of haem oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. Biochem. J. 348, 615-619.
3. Djousse, L., Levy, D., Cupples, L. A., Evans, J. C., D'Agostino, R. B., and Ellison, R. C. (2001). Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am. J. Cardiol. 87, 1196-1200.
4. Dore, S., Takahashi, M., Ferris, C. D., Zakhary, R., Hester, L. D., Guastella, D., and Snyder, S. H. (2009). Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 96, 2445-2450.
5. Duckers, H. J., Boehm, M., True, A. L., Yet, S.-F., Park, J. L., Webb, R. C., Lee, M.-E., Nabel, G. J., and Nabel, E. G. (2001). Heme oxygenase-1 protects against vascular constriction and proliferation. Nat. Med. 7, 693-698.
6. Durante, W. (2010). Targeting heme oxygenase-1 in vascular disease. Curr. Drug Targets 11, 1504-1516.
7. Fukui, R., Amakawa, M., Hoshiga, M., Shibata, N., Kohbayashi, E., Seto, M., Sasaki, Y., Ueno, T., Negoro, N., Nakakoji, T., Li, M., Nishiguchi, F., Ishihara, T., and Ohsawa, N. (2000). Increased migration in late G1 phase in cultured smooth muscle cells. Am. J. Physiol. 279, C999-C1007.
8. Fukui, R., Shibata, N., Kohbayashi, E., Amakawa, M., Furutama, D., Hoshiga, M., Negoro, N., Nakak-ouji, T., Ii, M., Ishitara, T., and Ohsawa, N. (1997). Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1). Atherosclerosis 132, 53-59.
9. Granada, J. F., Ensenat, D., Keswani, A. N., Kaluza, G. L., Raizner, A. E., Liu, X. M., Peyton, K. J., Azam, M. A., Wang, H., and Durante, W. (2005). Single perivascular delivery of mito-mycin C stimulates p21 expression and inhibits neointima formation in rat arteries. Arterioscler. Thromb. Vasc. Biol. 25, 2343-2348.
10. Hirschfield, G. M., and Alexander, G. J. (2006). Gilbert's syndrome: an overview for clinical biochemists. Ann. Clin. Biochem. 43, 340-343.
11. Hopkins, P. N., Wu, L. L., Hunt, S. C., James, B. C., Vincent, G. M., and Williams, R. R. (1996). Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 16, 250-255.
12. Hu, Y., Zou, Y., Dietrich, H., Wick, G., and Xu, Q. (1999). Inhibition of neointima hyperplasia in mouse vein grafts by locally applied suramin. Circulation 100, 861-868.
13. Institute of Laboratory Animal Resources. (1996). Guide for the Care and use of Laboratory Animals. Washington: National Academy Press.
14. Jansen, T., Hortmann, M., Oelze, M., Opitz, B., Steven,S., Schell, R., Knorr, M., Karbach, S., Wenzel, P., Mun-zel, T., and Daiber, A. (2010). Conversion of biliverdin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of biliverdin. J. Mol. Cell. Cardiol. 49, 186-195.
15. Kawamura, K., Ishikawa, K., Wada, Y., Kimura, S., Matsumoto, H., Kohro, T., Itabe, H., Kodama, T., and Maruyama, Y. (2005). Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arte-rioscler. Thromb. Vasc. Biol. 25, 155-160.
16. Kuwano, T., Miura, S., Shirai, K., Ike, A., Mori, K., Shimizu, T., Zhang, B., Iwata, A., Nishikawa, H., Kawa-mura,A.,andSaku,K.(2011). Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule. J. Atheroscler. Thromb. 18, 574-583.
17. Lin, J. P., O'Donnell, C. J., Schwaiger, J. P., Cupples, L. A., Lingenhel, A., Hunt, S. C., Yang, S., and Kronen-berg, F. (2006). Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114, 1476-1481.
18. Liu, X. M., Chapman, G. B., Wang, H., and Durante, W. (2002). Adenovirus-mediated heme oxygenase-1 gene expression stimulates apoptosis in vascular smooth muscle cells. Circulation 105, 79-84.
19. Liu, X. M., Peyton, K. J., Shebib, A. R., Wang, H., and Durante, W. (2011a). Compound C stimulates heme oxygenase-1 gene expression via the Nrf2-ARE pathway to preserve human endothelial cell survival. Biochem. Pharmacol. 82, 371-379.
20. Liu, X. M., Peyton, K. J., Shebib, A. R., Wang, H., Korthuis, R. J., and Durante, W. (2011b). Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival. Am. J. Physiol. Heart Circ. Physiol. 300, H84-H93.
21. Nakao, A., Murase, N., Ho, C., Toyokawa, H., Billiar, T. R., and Kanno, S. (2005). Biliverdin administration prevents the formation of intimal hyperplasia induced by vascular injury. Circulation 112, 587-591.
22. Nam, S. Y., and Sabapathy, K. (2011). P53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1. Oncogene 30, 4476-4486.
23. Novotny, L., and Vitek, L. (2003). Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp. Biol. Med. (Maywood) 228, 568-571.
24. Ollinger, R., Bilban, M., Erat, A., Froio, A., McDaid, J., Tyagi, S., Csizma-dia, E., Graca-Souza, A. V., Liloia, A., Soares, M. P., Otterbein, L. E., Usheva, A., Yamashita, K., and Bach, F. H. (2005). Bilirubin; a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112, 1030-1039.
25. Ollinger, R., Kogler, P., Troppmair, J., Hermann, M., Wurm, M., Drasche, A., Konigsrainer, I., Amberger, A., Weiss, H., Ofner, D., Bach, F. H., and Margreiter, R. (2007a). Biliru-bin inhibits tumor cell growth via activation of ERK. Cell Cycle 6, 3078-3085.
26. Ollinger, R., Wang, H., Yamashita, K., Wegiel, B., Thomas, M., Margre-iter, R., and Bach, F. H. (2007b). Therapeutic applications of biliru-bin and biliverdin in transplantation. Antioxid. Redox Signal. 9, 2175-2185.
27. Ollinger, R., Yamashita, K., Bilban, M., Erat, A., Kogler, P., Thomas, M., Csizmadia, E., Usheva, A., Margre-iter, R., and Bach, F. H. (2007c). Bilirubin and bilirubin treatment of atherosclerotic disease. Cell Cycle 6, 39-43.
28. Ostrow, J. D., Pascolo, L., Brites, D., and Tiribelli, C. (2004). Molecular basis of bilirubin-induced neurotoxicity. Trends Mol. Med. 10, 65-70.
29. Papadakis, J. A., Ganotakis, E. S., Jagroop, I. A., Mikhailidis, D. P., and Winder, A. F. (1999). Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am. J. Hypertens. 12, 673-681.
30. Perlstein, T. S., Pande, R. L., Beckman, J. A., and Creager, M. A. (2008). Serum total bilirubin level and pre-velant lower-extremity peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 28, 166-172.
31. Peyton, K. J., Ensenat, D., Azam, M. A., Keswani, A. N., Kannan, S., Liu, X. M., Wang, H., Tulis, D. A., and Durante, W. (2009). Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler. Thromb. Vasc. Biol. 29, 488-494.
32. Peyton, K. J., Yu, Y., Yates, B., She-bib, A. R., Liu, X. M., Wang, H., and Durante,W. (2011). Compound C inhibits vascular smooth muscle cell proliferation and migration in an AMP-activated protein kinase-independent fashion. J. Pharmacol. Exp. Ther. 338, 476-484.
33. Pflueger, A., Croatt, A. J., Peterson, T. E., Smith, L. A., d'Uscio, L. V., Katu-sic, Z. S., and Nath, K. A. (2005). The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am. J. Physiol. Renal Physiol. 288, F552-F558.
34. Rao, P., Suzuki, R., Mizobuchi, S., Yam-aguchi, T., and Sasaguri, S. (2006). Bilirubin exhibits a novel anti-cancer effect on human adenocarcinoma. Biochem. Biophys. Res. Com-mun. 342, 1279-1283.
35. Rodriguez, A. I., Gangopadhyay, A., Kel-ley, E. E., Pagano, P. J., Zucker-braun, B. S., and Bauer, P. M. (2010). HO-1 and CO decrease platelet-derived growth factor-induced vascular smooth muscle cell migration via inhibition of Nox1. Arterioscler. Thromb. Vasc. Biol. 30, 98-104.
36. Rodriguez-Compos, A., Ruiz-Enriquez, P., Faraudo, S., and Badimon, L. (2001). Mitogen-induced p53 downregulation precedes vascular smooth muscle cell migration from healthy tunica media and proliferation. Arteriosler. Thromb. Vasc. Biol. 21, 214-219.
37. Sanz-Gonzalez, S. M., Barquin, L., Garcia-Cao, I., Roque, M., Gonzalez, J. M., Fuster, J. J., Castells, M. T., Flores, J. M., Serrano, M., and Andres, V. (2007). Increased p53 gene dosase reduced neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc. Res. 75, 803-812.
38. Schwertner, H. A., Jackson, W. G., and Tolan, G. (1994). Association of low serum concentration of biliru-bin with increased risk of coronary artery disease. Clin. Chem. 40, 18-23.
39. Sherr, C. J. (1994). G1 phase progression: cycling on cue. Cell 79, 551-555.
40. Soares, M. P., Seldon, M. P., Gregoire, I. P., Vssilevskaia, T., Berberat, P. O., Yu, J., and Bach, F. H. (2004). Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J. Immunol. 172, 3553-3563.
41. Stocker, R. (2004). Antioxidant activities of bile pigments. Antioxid. Redox Signal. 6, 841-849.
42. Stocker, R., Glazer, A. N., and Ames, B. N. (1987a). Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. U.S.A. 84, 5918-5922.
43. Stocker, R., Yamamato, Y., McDonagh, A. F., Glazer, A. N., and Ames, B. N. (1987b). Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043-1046.
44. + influx in the growth arrest of human vascular smooth muscle cells by bilirubin. J. Biol. Chem. doi:10.1074/jbc.M111.266510
45. Taille, C., Almolki, A., Benhamed, M., Zedda, C., Megret, J., Berger, P, Leseche, G., Fadel, E., Yamaguchi, T, Marthan, R., Aubier, M., and Boczkowski, J. (2003). Hemeoxyge-nase inhibits human airway smooth muscle proliferation via a bilirubin-dependent modulation of ERK1/2 phosphorylation. J. Biol. Chem. 278, 27160-27168.
46. Togane, Y., Toshisuki, M., Suematsu, M., Ishimura, Y., Yamazaki, J., and Katayama, S. (2000). Protective roles of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am. J. Physiol. Heart Circ. Physiol. 278, H623-H632.
47. Tulis, D. A., Durante, W., Peyton, K. J., Evans, A. J., and Schafer, A. I. (2001a). Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation 104, 2710-2715.
48. Tulis, D. A., Durante, W., Peyton, K. J., Evans, A. J., and Schafer, A. I. (2001b). Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis 155, 113-122.
49. Vachharajan, T. J., Work, J., Issekutz, A. C., and Granger, D. N. (2000). Heme oxygenase modulates selectin expression in different vascular beds. Am. J. Physiol. Heart Circ. Physiol. 278, H1613-H1617.
50. Vera, T., Granger, J. P., and Stec, D. E. (2009). Inhibition of biliru-bin metabolism induces moderate hyperbilirubinemia and attenuates angiotensin II-dependent hypertension in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R738-R743.
51. Villanueva, J., Yung, Y., Walker, J. L., and Assoian, R. K. (2007). ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol. Biol. Cell 18, 1457-1463.
52. Weber, J. D., Raben, D. M., Phillips, P. J., and Baldassare, J. J. (1997). Sustained activation of extracellular-signal regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 326, 61-68.
53. Wei, Y., Liu, X. M., Peyton, K. J., Wang, H., Johnson, F. K., Johnson, R. A., and Durante, W. (2009). Hypochlorous acid-induced heme oxygenase-1 gene expression promotes endothelial cell survival. Am. J. Physiol. Cell Physiol. 297, C907-C915.
54. Wu, T., Fung, K. P., Wu, J., Yang, C. C., and Weisel, R. D. (1996). Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem. Pharmacol. 51, 859-862.
55. Yamaguchi, T., Terakado, M., Horio, F., Aoki, K., Tanaka, M., and Naka-jima, H. (1996). Role of biliru-bin as an antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase. Biochem. Biophys. Res. Commun. 223, 129-135.
56. Yang, Z. Y., Simari, R. D., Perkins, N. D., San, H., Gordon, D., Nabel, G. J., and Nabel, E. G. (1996). Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. U.S.A. 93, 7905-7910.
57. Yu, J., Zhang, L., Hwang, P. M., Rago, C., Kinzler, K. W., and Vogelstein, B. (1999). Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. U.S.A. 96, 14517-14522.